AAP
HCAT icon

Arax Advisory Partners’s Health Catalyst HCAT Stock Holding History

Arax Advisory Partners’s Portfolio HCAT Stock Details HCAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$161 Buy
127
+90
+243% +$169 ﹤0.01% 3567
2025
Q4 		$88 Sell
37
-594
-94% -$1.62K ﹤0.01% 3850
2025
Q3 		$1.8K Buy
+631
New +$2.16K ﹤0.01% 3136
2025
Q2 		– Sell
-223
Closed -$1.01K – 3119
2025
Q1 		$1.01K Sell
223
-440
-66% -$2.33K ﹤0.01% 2299
2024
Q4 		$4.69K Buy
663
+164
+33% +$1.31K ﹤0.01% 1762
2024
Q3 		$4.06K Hold
499
– – ﹤0.01% 1803
2024
Q2 		$3.19K Buy
+499
New +$3.2K ﹤0.01% 1798

Other funds holding HCAT

FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $157M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WCA
Whetstone Capital Advisors Shawnee Mission, Kansas $288M AUM 44.06% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Impax Asset Management Group
Impax Asset Management Group London, United Kingdom $14.3B AUM 19.8% 1-Year Est. Return
NI
Nepsis Inc Minneapolis, Minnesota $295M AUM 35.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arax Advisory Partners's HCAT Position: Q1 2026 in Review

Arax Advisory Partners increased its Health Catalyst (HCAT) stake by 243% in Q1 2026, buying an estimated $169 and bringing the position to 127 shares worth $161. The position accounts for ﹤0.01% of the portfolio, ranked #3567.

Arax Advisory Partners first reported a position in HCAT in Q2 2024 and has held it in 7 quarters since. The position peaked at $4.69K in Q4 2024. 130 funds tracked by Wall St. Rank hold HCAT as of Q1 2026.

  • Arax Advisory Partners held 127 shares of Health Catalyst worth $161 as of Q1 2026.
  • Arax Advisory Partners bought 90 Health Catalyst shares in Q1 2026, an estimated $169.
  • Health Catalyst made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3567 holding.
  • Arax Advisory Partners first reported a position in Health Catalyst in Q2 2024 and has held it in 7 quarters since.
  • Arax Advisory Partners's Health Catalyst position peaked at $4.69K in Q4 2024.
  • 130 funds tracked by Wall St. Rank held Health Catalyst as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.